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Introduction
The tumor suppressor TP53, which encodes a transcription fac-
tor, is the most commonly mutated gene in cancer cells (Levine 
and Oren, 2009). The p53 circuit responds to a myriad of stress 
signals, including DNA damage, oncogene activation, meta-
bolic fluctuations, and mitotic aberrations, and drives programs 
that can lead to temporary arrest, senescence, or cell death 
(Levine and Oren, 2009; Uetake and Sluder, 2010; Ganem et 
al., 2014; Gurpinar and Vousden, 2015; Kruiswijk et al., 2015). 
In the absence of stress, p53 is continuously targeted for protea-
somal degradation by the ubiquitin ligase Mdm2 (Levav-Cohen 
et al., 2014; Karni-Schmidt et al., 2016). Layers of positive and 
negative regulation of p53 are imposed through an extensive 
array of posttranslational modifications (Gu and Zhu, 2012; 
Jenkins et al., 2012; Nguyen et al., 2014).
Recent work has shown that p53 monitors mitosis, al-
though the underlying mechanisms remain poorly understood. 
Work in hTERT-RPE1 immortalized retinal pigment epithelial 
cells (RPE1 cells) has shown that if the duration of mitosis ex-
ceeds a relatively sharp temporal cutoff (∼1.5 h), the resulting 
daughter cells arrest in a p53-dependent fashion at the subse-
quent G1/S transition (Uetake and Sluder, 2010). Similarly, 
triggering cytokinesis failure by chemical disruption of the actin 
cytoskeleton leads to a p53-dependent arrest through activation 
of the Hippo tumor suppressor pathway (Ganem et al., 2014).
Centrosome loss has also been shown to activate p53 
(Bazzi and Anderson, 2014; Lambrus et al., 2015; Wong et 
al., 2015). Centrioles organize pericentriolar material to form 
centrosomes that nucleate and anchor microtubules (Wood-
ruff et al., 2014; Conduit et al., 2015). Centriole duplication 
is tightly controlled to ensure that mitotic cells have precisely 
two centrosomes. Centrioles duplicate in S-phase, when the 
polo family kinase Plk4 triggers formation of a single daugh-
ter adjacent to each mother centriole (Gönczy, 2012; Zitouni 
et al., 2014; Fu et al., 2015). To analyze the effect of centro-
some removal in normal and cancer cells, we developed cen-
trinone, a potent specific Plk4 inhibitor (Wong et al., 2015). 
Centrinone treatment blocks centriole duplication, leading 
In normal human cells, centrosome loss induced by centrinone—a specific centrosome duplication inhibitor—leads to 
irreversible, p53-dependent G1 arrest by an unknown mechanism. A genome-wide CRI SPR/Cas9 screen for centrinone 
resistance identified genes encoding the p53-binding protein 53BP1, the deubiquitinase USP28, and the ubiquitin ligase 
TRIM37. Deletion of TP53BP1, USP28, or TRIM37 prevented p53 elevation in response to centrosome loss but did not 
affect cytokinesis failure–induced arrest or p53 elevation after doxorubicin-induced DNA damage. Deletion of TP53BP1 
and USP28, but not TRIM37, prevented growth arrest in response to prolonged mitotic duration. TRIM37 knockout cells 
formed ectopic centrosomal-component foci that suppressed mitotic defects associated with centrosome loss. TP53BP1 
and USP28 knockouts exhibited compromised proliferation after centrosome removal, suggesting that centrosome- 
independent proliferation is not conferred solely by the inability to sense centrosome loss. Thus, analysis of centrinone 
resistance identified a 53BP1-USP28 module as critical for communicating mitotic challenges to the p53 circuit and 
TRIM37 as an enforcer of the singularity of centrosome assembly.
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to progressive loss of centrosomes as cells divide. Most cell 
lines with cancer-associated mutations (which frequently 
target the p53 circuit) continue to proliferate after centri-
none-mediated centrosome removal, albeit at a reduced rate 
because of an increase in mitotic errors (Wong et al., 2015), 
which is consistent with prior work (Khodjakov and Rieder, 
2001; Sir et al., 2013).
In contrast to cancer-derived cell lines, RPE1 and three 
primary cell cultures exhibited irreversible G1 arrest after cen-
trinone-induced centrosome loss (Wong et al., 2015). Com-
parable results were also observed after auxin-induced Plk4 
degradation (Lambrus et al., 2015). The centrosome loss– 
associated G1 arrest required p53 (Lambrus et al., 2015; Wong 
et al., 2015). Similarly, centriole removal from mouse embryos 
by genetic disruption of the centriole component Sas4 led to a 
wave of p53-dependent apoptosis at embryonic day 8.5, sug-
gesting that a p53-based mechanism can detect centrosome loss 
beginning at midgestation (Bazzi and Anderson, 2014).
Although several potential mechanisms have been ex-
cluded (Lambrus et al., 2015; Wong et al., 2015), the molecular 
details of centrosome loss–mediated p53 stabilization remain 
unclear. To address this, we performed an unbiased genome-wide 
CRI SPR/Cas9-based screen to identify genes whose loss en-
ables RPE1 cells to proliferate in centrinone. This approach 
identified a two-protein module that can communicate centro-
some loss or extended mitotic duration to the p53 circuit and 
revealed a ubiquitin ligase whose loss perturbs the singularity 
of centrosome assembly, resulting in ectopic assemblies that 
bypass the detrimental consequences of acentrosomal mitosis.
Results and discussion
A genome-wide CRI SPR/Cas9 screen 
identifies genes required to activate p53 
upon centrosome loss
To understand how centrosome loss elevates p53, we performed 
a genome-wide CRI SPR/Cas9-based screen to identify genes 
whose mutation allows RPE1 cells to grow in the presence of 
centrinone (Fig. 1, A and B). We reasoned that genes required 
for p53-dependent arrest of centrosomeless cells would fall into 
two categories: genes specifically required to elevate p53 lev-
els in response to centrosome loss (type 1) and p53 itself and 
its downstream effectors, such as p21, required to convert p53 
activation into a durable G1 arrest (type 2; Levine and Oren, 
2009; Kruiswijk et al., 2015). To identify type 1 genes, we used 
a secondary screen challenging colonies that grew in the pres-
ence of centrinone with an Mdm2 inhibitor (Mdm2i) that sta-
bilizes p53 by preventing it from binding its negative regulator 
Mdm2 (Ding et al., 2009; Khoo et al., 2014). Type 1 colonies 
would grow in centrinone but not in Mdm2i; in contrast, type 2 
colonies would grow in both centrinone and Mdm2i (Fig. 1 B).
We performed two independent screens using a lentiviral 
human CRI SPR/Cas9 library (see Methods). After growth in 
Figure 1. Genome-wide CRI SPR/Cas9 screen 
for genes involved in activating p53 upon 
centrosome loss. (A, top) Immunofluorescence 
images of RPE1 cells, stained for DNA (red) 
and the centrosomal protein Cep192 (green), 
after treatment with DMSO or centrinone for 
5 d.  Bar, 10 µm. (bottom) Schematic high-
lighting the two classes of genes that would 
be identified in a centrinone-resistance screen. 
(B) Summary of the screen designed to identify 
genes that activate p53 in response to centro-
some loss. (C) Table summarizing the results of 
two independent screens. All 15 colonies had 
one of the three listed genes deleted; no col-
ony had more than one. (D) Schematic of the 
three proteins 53BP1, USP28, and TRIM37, 
identified by the screen.
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centrinone for 20–25 d, colonies were picked and grown with-
out centrinone for 5–10 d; 32 colonies were obtained in the first 
screen and 75 in the second. After expansion, a representative 
fraction of each colony was treated with Mdm2i and scored 7 
d later. This approach identified 15 type 1 colonies (Fig. 1 C). 
Direct amplification of the guide RNAs (gRNAs) in each col-
ony (Fig. S1 A) identified gRNAs targeting one of three genes: 
TP53BP1, encoding the DNA damage regulator 53BP1; USP28, 
encoding a deubiquitinase; and TRIM37, encoding a ubiquitin 
ligase (Fig. 1, C and D). For TP53BP1 and USP28, two different 
gRNAs were recovered (Fig. 1 C). In parallel, the 32 colonies 
that grew in centrinone in the first screen (type 1 and type 2) 
were pooled, and the amplified gRNAs were subjected to deep 
sequencing. In addition to identifying two gRNAs targeting 
TP53BP1 and USP28, this approach identified five gRNAs tar-
geting TP53 and three targeting CDKN1A, both expected type 2 
hits (Fig. S1 B). The one gRNA targeting TRIM37 was also on 
this list, but would not have stood out as a hit worth pursuing 
without the parallel colony sequencing approach.
Loss of 53BP1, USP28, or TRIM37 
suppresses p53 elevation and proliferation 
arrest triggered by centrosome loss
To confirm the three type 1 hits from the screens and rule out pos-
sible contributions from other gRNAs, we used single gRNAs 
with centrinone selection to generate new RPE1 knockout cell 
lines for TP53BP1, TRIM37, and USP28 (Fig.  2  A and Fig. 
S2 A). All three cell lines were validated by immunoblotting 
(Fig. 2 A) and proliferated indefinitely in the absence of centri-
none, indicating that these genes are not essential. By immuno-
fluorescence, 53BP1 and USP28 exhibited a nuclear signal that 
was absent in the knockout lines (Fig. S2 B) and did not appear 
to change in intensity after centrosome loss (not depicted). For 
TRIM37, despite testing 10 different commercial antibodies, 
we were unable to observe any immunostaining that differed 
between control and knockout cells. Centrinone treatment de-
pleted centrosomes (identified as foci costaining for the markers 
γ-tubulin and Cep192) in all knockout cell lines (Fig. S2 C).
Next, we used a passage-based cell counting assay to 
measure the proliferative capacity of the three knockout lines 
in the presence of centrinone and Mdm2i. Consistent with 
prior work (Wong et al., 2015), control RPE1 cells failed to 
proliferate when they were passaged 4 d after centrinone or 
Mdm2i addition (Fig. 2, B and C). The TP53BP1Δ, USP28Δ, 
and TRIM37Δ cell lines all ceased proliferation after Mdm2i 
addition, with kinetics identical to that of controls. In con-
trast, the three knockouts continued to proliferate, albeit at 
slower rates, when they were passaged 4 d after centrinone 
addition (Fig.  2, B and C). The reduced proliferation rates 
were comparable to those observed previously for centri-
none-treated cancer cell lines (Wong et al., 2015), suggesting 
that they result from error-prone mitosis after centrosome re-
moval. Consistent with these results, immunoblotting revealed 
that elevation of p53 and p21 was still observed after Mdm2i 
treatment but was greatly suppressed in the three knockout 
cell lines after 2-d centrinone treatment (Fig.  2  D). We also 
quantified nuclear p53 signal by immunofluorescence 5 d 
after centrinone addition. The centrinone-dependent approx-
imately fivefold increase in nuclear p53 observed in control 
RPE1 cells was absent in the TP53BP1Δ and USP28Δ cell 
lines and was largely, but not completely, suppressed in the 
TRIM37Δ cell line (Figs. 2 E and S2 D).
53BP1 and USP28, but not TRIM37, are 
essential for p53 activation in response to 
prolonged mitotic duration
Beyond centrosome loss, p53 is activated by stresses such as 
DNA damage, cytokinesis failure, and extended mitotic duration 
(Jackson and Bartek, 2009; Uetake and Sluder, 2010; Ganem et 
al., 2014; Williams and Schumacher, 2016). To understand their 
roles, we assessed the impact of 53BP1, USP28, and TRIM37 
loss on each of these distinct means of p53 activation. We found 
that all three knockouts exhibited a normal p53 response after 
DNA damage caused by doxorubicin (Fig. 3 A), a DNA-inter-
calating topoisomerase poison (Jackson and Bartek, 2009). To 
analyze cytokinesis failure, wild-type and mutant cell lines ex-
pressing RFP::histone H2b were treated for 24 h with the actin 
polymerization inhibitor cytochalasin D, and the fate of the re-
sulting tetraploid cells was followed by live imaging for 3 d 
(Fig.  3  B). Approximately 97% of tetraploid cells expressing 
a stable shRNA targeting p53 entered mitosis. In contrast, the 
TP53BP1Δ, USP28Δ, and TRIM37Δ cell lines all exhibited low 
percentages of tetraploid cells entering mitosis, comparable to 
control RPE1 cells (Fig. 3 B), indicating that these genes are not 
required for the cell cycle arrest induced by cytokinesis failure.
To analyze p53-mediated arrest caused by extended mi-
totic duration, we used the procedure schematized in Fig. 3 C 
(based on Uetake and Sluder [2010]) in which treatment with 
the Eg5 inhibitor monastrol was used to prolong mitosis for 
varying amounts of time, and daughter cells were followed for 
48 h after drug washout to determine whether they arrested or 
divided. In control RPE1 and TRIM37Δ cells, mitotic dura-
tions greater than 90 min led to penetrant arrest of the resulting 
daughter cells. In contrast, both TP53BP1Δ and USP28Δ cells 
failed to arrest in response to extended mitotic duration. Thus, 
53BP1 and USP28 are required to arrest cells after either cen-
trosome loss or extended mitotic duration.
Centrosome loss slows spindle assembly and increases 
mitotic duration (Wong et al., 2015; see Fig. 5, A and C), rais-
ing the question of whether centrosome loss–mediated p53 ac-
tivation occurs via extending mitosis (Fig. 3 D). In an attempt 
to address this, we pretreated cells for 24  h with centrinone, 
at which point the majority of cells have one centrosome and 
do not yet have elevated p53 (Fig. S2 E). The cells were then 
incubated with centrinone plus an Mps1 inhibitor (NMS-P715, 
which suppresses the spindle checkpoint) for 24 h to determine 
whether shortening mitosis could block the p53 elevation that 
occurs as the first wave of cells go from having one to zero 
centrosomes. Mps1 inhibition suppressed centrinone-mediated 
p53 elevation but also resulted in penetrant cytokinesis failure 
that likely prevented centrosome removal (Fig. S2 F), thereby 
complicating interpretation of this result.
If centrosome loss is detected solely because of its effect 
on mitotic duration, prior work (Lambrus et al., 2015; Wong et 
al., 2015) suggests that the p53 circuit must be able to “integrate” 
mitotic duration over multiple generations. In our prior study, 
we found that only 13% of cells undergoing their first division 
in the absence of centrosomes spent longer in mitosis than the 
mitotic duration threshold, yet 70% of their daughters arrested; 
in addition, whether daughter cells arrested was not strongly 
correlated with mitotic duration of the mother cells (Wong et 
al., 2015). Because mitosis is also extended in one-centrosome 
cells, it is possible that two sequential moderately prolonged 
mitoses below the mitotic duration threshold could arrest 
daughter cells via the same mechanism that arrests daughter 
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Figure 2. Loss of TP53BP1, USP28, or TRIM37 suppresses p53 elevation and proliferation arrest triggered by centrosome loss. (A, top) Outline of the 
procedure used to generate RPE1 knockouts. (A, bottom) Immunoblots of extracts from control (Ctrl) and knockout RPE1 lines. Bands corresponding to 
each protein (arrowheads) and nonspecific bands (asterisks) are indicated. α-Tubulin serves as a loading control. (B) Outline of cell proliferation analysis 
and assessment of p53 and p21 levels after acute treatment with centrinone or Mdm2i. (C) Graphs plotting the results of passaging assays monitoring the 
growth of control and knockout RPE1 cell lines after addition at day 0 of DMSO (vehicle), centrinone, or Mdm2i. (D) Immunoblots probed with the indicated 
antibodies after addition of Mdm2i (left) or centrinone (right). α-Tubulin (α-tub) serves as a loading control. (E) Immunofluorescence analysis of Cep192 
and p53 after 5-d centrinone treatment. Representative images (left) and graph (right) plotting the distributions of nuclear p53 fluorescence for one of three 
experiments (for quantification of the other two experiments, see Fig. S2 E). Graph shows 5–95% box-and-whiskers plots. Bar, 10 µm.
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cells after a single mitosis above the threshold. Alternatively, 
centrosome loss and mitotic duration may independently con-
tribute to p53 elevation via a module that requires 53BP1 and 
USP28 (Fig. 3 D). Resolving this question will likely require 
additional approaches focused on 53BP1 and USP28 as well 
as live-cell monitoring of p53 levels after centrosome removal.
TRIM37Δ cells form foci containing 
centrosomal markers after centrinone-
mediated centrosome loss
While analyzing DMSO-treated knockout lines, we noticed 
that Cep192 localized to small foci in TRIM37Δ cells, often 
in a halo surrounding the centrosome, a phenomenon not ob-
served in control RPE1 cells or the other two knockout cell lines 
(Fig. 4 A, top row). Costaining with the centriolar satellite pro-
tein PCM-1 (Balczon et al., 1994; Kubo et al., 1999; Dammer-
mann and Merdes, 2002) suggested that loss of TRIM37 causes 
Cep192 to accumulate at satellites (Fig. S3 A), whereas other 
centrosomal markers did not localize to satellites (Fig. S3 B), 
Plk4 exhibited a different behavior, concentrating in a single 
bright noncentriolar focus (Fig.  4  B, yellow arrow) in ∼40% 
of cells (Fig. S3 B). In centrinone-treated interphase TRIM37Δ 
cells, Cep192 localized to an array of small foci, as did Plk4 
and two other components at the top of the centriole assembly 
Figure 3. 53BP1 and USP28, but not TRIM37, are essential for activating p53 in response to prolonged mitotic duration. (A) Analysis of p53 and p21 
levels after induction of DNA damage with doxorubicin; schematic describes experimental protocol and GAP DH serves as a loading control. (B) Analysis 
of cytokinesis failure–induced division arrest; schematic describes experimental protocol. Red dots show results from two independent experiments. Immuno-
blot confirms efficient p53 depletion. (C) Analysis of extended mitotic duration–induced division arrest; schematic describes experimental protocol. Vertical 
bars represent individual daughter cells. Bar height shows the time the mother cells spent in mitosis, and bar color indicates whether they arrested (red) or di-
vided (gray). Black dashed line marks the mitotic duration cutoff in control RPE1 cells, after which resulting daughter cells arrest in G1. (D) Schematic shows 
two possible models for how centrosome loss might trigger p53 activation, either directly (left) or indirectly through successive prolonged mitoses (right).
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hierarchy, Cep152 and Sas6 (Fig. 4, A and B, and Fig. S3 B). 
The centriole outer wall component CPAP and three pericen-
triolar material (PCM) components (γ-tubulin, pericentrin, and 
Cdk5rap2) did not localize to these interphase foci (Figs. 4 B 
and S3 B). The interphase foci in centrinone-treated TRIM37Δ 
cells were able to serve as sites for microtubule regrowth after 
nocodazole washout (Fig. 4 C). In mitotic TRIM37Δ cells treated 
with DMSO, the localization of centrosome markers was sim-
ilar to that in controls except for the presence in ∼90% of cells 
(24/26) of a large bright noncentriolar focus of Plk4 (Figs. 4 D 
and S3 D, yellow arrow). Consistent with a prior study showing 
that TRIM37 inhibition can cause centriole reduplication (Bal-
estra et al., 2013) ∼15–20% of mitotic DMSO-treated TRIM37Δ 
cells also appeared to contain one or occasionally two extra cen-
trioles. In contrast, centrinone-treated mitotic TRIM37Δ cells 
contained an array of small foci that stained for the PCM mark-
ers γ-tubulin, pericentrin, and Cdk5rap2 in addition to Cep192, 
Cep152, Plk4, and Sas6 (Fig. 4 D and Fig. S3, C and D); how-
ever, CPAP was not detected. Similar foci were not detected for 
any of these markers in DMSO- or centrinone-treated control, 
TP53BP1Δ, or USP28Δ cells (Fig. S3, C and D).
Consistent with our finding that TRIM37 loss leads to the 
accumulation of Cep192 at satellites, TRIM37 was previously 
reported to associate with two centriolar satellite components 
and Cep192 (Firat-Karalar et al., 2014). Our results suggest that 
after centrosome removal, the Cep192-containing satellites in 
TRIM37Δ cells acquire additional components (including Plk4, 
Cep152, and Sas6) and the ability to nucleate microtubules. In 
mitotic TRIM37Δ cells, Cep192-containing foci acquire PCM 
components and are observed at spindle poles, suggesting that 
TRIM37 loss leads to the assembly of centrosome-like struc-
tures in centrinone-treated cells that attenuate the detrimental 
consequences of centrosome removal.
Deletion of TRIM37, but not TP53BP1 
or USP28, suppresses mitotic defects in 
centrosomeless cells
To test whether, in contrast to TP53BP1Δ or USP28Δ, 
TRIM37Δ suppresses p53 elevation by improving mitotic fidel-
ity after centrosome loss, we imaged mitosis in cells expressing 
RFP::histone H2b after 5-d centrinone or DMSO treatment. In 
addition to the three knockout cell lines, we imaged an RPE1 
cell line stably expressing a p53 shRNA to allow continued 
proliferation after centrosome loss (sh-TP53; Fig. 3 B). Mito-
sis in DMSO-treated TP53BP1Δ, USP28Δ, and sh-TP53 cells 
was comparable to that in DMSO-treated control RPE1 cells 
in terms of duration and the percentage of cells undergoing a 
normal bipolar division (Video 1; Fig. 5, B and C; and Fig. S3 
E). Although most (∼81%) DMSO-treated TRIM37Δ cells also 
underwent a normal bipolar division, some (∼18%) underwent 
a multipolar mitosis or had metaphase plates that transiently ap-
peared multipolar before a normal bipolar division (Video 1 and 
Fig. 5 B), consistent with the presence of extra centrosomes as a 
result of reduplication events (Fig. S3 D; Balestra et al., 2013).
Centrinone-treated TP53BP1Δ, USP28Δ, and p53 
shRNA–expressing cells took longer to align their chromo-
somes at the metaphase plate (Fig.  5  A and Video  1), as ex-
pected after centrosome removal (Bazzi and Anderson, 2014; 
Lambrus et al., 2015; Wong et al., 2015), and mitotic duration 
was extended ∼2.2-fold compared with centrosome-containing 
controls (Fig. 5 C). Approximately 20% of the TP53BP1Δ and 
USP28Δ cells, and 14% of the p53 shRNA–expressing cells, 
exhibited a severe segregation failure phenotype in which cells 
initiated what appeared to be anaphase, but the chromosome 
masses collapsed back together and division failed (Fig. 5, A 
and B; and Video 1). In contrast to the other cell lines, mean mi-
totic duration was only slightly increased after centrinone treat-
ment in TRIM37Δ cells, even after 2 wk (1.2-fold; Fig. 5 C), and 
centrinone-treated TRIM37Δ cells did not exhibit a segregation 
failure phenotype. Instead, ∼30% of TRIM37Δ cells exhibited 
segregation figures consistent with extra spindle poles; about 
half of these resolved into bipolar configurations before segre-
gation initiated, whereas multipolar segregation was observed 
for the remainder (Fig. 5 B).
Thus, whereas TP53BP1Δ and USP28Δ cells exhibit sig-
nificant delays in chromosome alignment after centrosome loss 
and a high percentage of chromosome segregation failure, chro-
mosomes align much more quickly, albeit often in a multipolar 
configuration, in TRIM37Δ cells (see Fig. S3 E for a compari-
son of timing in bipolar and multipolar mitoses). These results 
suggest that the ectopic centrosome component–containing foci 
that form after centrosome removal in TRIM37Δ cells can func-
tion like centrosomes to accelerate mitotic spindle assembly 
and chromosome alignment. That TRIM37Δ cells do not elevate 
p53 when centrosomes are removed could be because mitotic 
duration is reduced below the threshold for p53 activation; al-
ternatively, it is possible that in addition to facilitating mitosis, 
the ectopic foci are sufficiently centrosome-like to be able to 
suppress p53 activation.
Analysis in a 20-d passaging assay after addition of centri-
none revealed that TRIM37Δ cells continued to divide robustly 
(TRIM37Δ doubling time = 0.92 d (DMSO) and 1.27 d (centri-
none); wild-type (DMSO) doubling time = 0.76 d; Fig. S3 G) 
and maintained a normal-looking morphology (Fig.  5, D and 
E). In contrast, the proliferative capacity of the TP53BP1 and 
USP28 knockout lines appeared to be more compromised, and 
many cells exhibited an aberrant morphology, presumably be-
cause of accumulated mitotic errors (Fig. 5, D and E). Thus, in 
RPE1 cells, the inability to sense centrosome loss or extended 
mitotic duration is likely not sufficient to confer the ability to 
proliferate robustly in the absence of centrosomes that is ob-
served for many cancer cell lines.
TRIM37 is an E3 ubiquitin ligase of the TRIpartite motif 
(TRIM) protein family (Kallijärvi et al., 2005) previously impli-
cated in restricting centriole number (Balestra et al., 2013). We 
show that when centriole assembly is suppressed by Plk4 inhi-
bition, TRIM37 deletion promotes the formation of ectopic foci 
containing centrosomal components. It is unlikely that these foci 
contain bona fide centrioles, as they do not contain the essen-
tial outer centriole wall component CPAP, and Plk4 inhibition 
should block SAS-6 oligomerization to form the centriolar cart-
wheel (Brito et al., 2012; Gönczy, 2012; Fu et al., 2015). Cep192 
is thought to act redundantly with Cep152 as a centriolar receptor 
for Plk4 (Cizmecioglu et al., 2010; Hatch et al., 2010; Kim et al., 
2013; Sonnen et al., 2013; Park et al., 2014). We find that in cen-
trosomeless cells generated by Plk4 inhibition, TRIM37 removal 
leads to the formation of ectopic foci containing Cep192 and 
Cep152 that recruit Plk4 in interphase and PCM components in 
mitotic cells. These results highlight a critical role for TRIM37 in 
ensuring that Plk4 recruitment and PCM assembly occur only on 
the scaffold provided by the outer centriole wall, thereby ensuring 
the singularity of centriole duplication and centrosome assembly.
We identify 53BP1 and USP28 as critical components 
of the mechanism that leads to p53 elevation and G1 arrest in 
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Figure 4. TRIM37Δ cells form foci containing centrosomal markers. (A) Immunofluorescence images after 5-d treatment with DMSO (top row) or centrinone 
(bottom row). Cells were stained for DNA (red) and with antibodies to the centrosomal protein Cep192 (green; insets 2.5× magnified). (B) Immunofluo-
rescence images of interphase TRIM37Δ cells stained for DNA (red) and with antibodies to the indicated centrosomal proteins (green) after 5-d treatment 
with DMSO (top) or centrinone (bottom). Images are representative, and each marker was equivalently scaled for the two conditions. Yellow arrow points 
to bright ectopic Plk4 focus; blue arrow points to centrioles. (C) Immunofluorescence images of a microtubule regrowth experiment. Control RPE1 (left) 
and TRIM37Δ (middle) cells were pretreated for 5 d with DMSO (top) or centrinone (bottom) followed by 2-h treatment with nocodazole to depolymerize 
microtubules. Microtubules were allowed to grow for 4 min after nocodazole washout before fixation. Graph shows quantification of microtubule regrowth 
foci. (D) Immunofluorescence images of mitotic TRIM37Δ cells stained for DNA (red) and with antibodies to the indicated centrosomal proteins (green) after 
5-d treatment with DMSO (top) or centrinone (bottom). Each marker was equivalently scaled for the two conditions. Yellow arrow points to bright ectopic 
Plk4 focus; blue arrows point to centrioles. Bars, 10 µm.
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Figure 5. Knockout of TRIM37, but not TP53BP1 or USP28, suppresses mitotic defects in centrosomeless cells. (A) Selected images from timelapse series of 
representative DMSO-treated control RPE1 cells and centrinone-treated TP53BP1Δ, USP28Δ, and TRIM37Δ mutant cells, acquired as outlined in the sche-
matic. (B) Graph plotting the distribution of mitotic phenotypes observed for each condition along with representative images. (C) Graph plotting mitotic 
duration. Individual cell values (red triangles) are shown along with the mean and SD (black bars) for each condition. NEBD, nuclear envelope breakdown. 
(D) Graphs plotting the results of passaging assays monitoring the growth of control and knockout RPE1 cell lines after acute addition at day 0 of DMSO 
(vehicle) or centrinone. (E) Representative phase-contrast images of fields of DMSO-treated control RPE1 and knockout mutant cells after prolonged (>20 d) 
treatment with centrinone. Bars: (A and B) 10 µm; (E) 100 µm.
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response to centrosome removal and prolonged mitotic dura-
tion, suggesting a central role for a 53BP1-USP28 module in 
communicating mitotic challenges to the p53 circuit. 53BP1 
was first identified as a p53 binding partner (Iwabuchi et al., 
1994), although the significance of this interaction is unknown 
(Panier and Boulton, 2014). USP28 is a deubiquitinase that in-
teracts with the tandem BRCT domains of 53BP1 (Zhang et 
al., 2006; Knobel et al., 2014). USP28 has been proposed to 
promote the stability of proteins involved in the DNA dam-
age response based on work in a human cell type (Zhang et 
al., 2006); however, Usp28-null mice do not show phenotypes 
characteristic of loss of a DNA damage response (Knobel et al., 
2014). Understanding how 53BP1 and USP28 elevate p53 in 
response to centrosome loss and extended mitotic duration, and 
determining whether centrosome loss is an independent input 
into the p53 circuit or triggers p53 elevation because it leads to 
sequential prolonged mitoses, are important future goals arising 
from the results described here.
Materials and methods
Chemical inhibitors
The chemical inhibitors used in this study were centrinone (150 
nM; LCR-263; synthesized by Sudia MediTech; Wong et al., 2015); 
MDM2 inhibitor ((2-(4-(tert-butyl)-2-ethoxyphenyl)-4,5-bis(4-chloro-
phenyl)-4,5-dimethyl-4,5-dihydro-1H-imidazol-1-yl)(4-(2-(methylsul- 
fonyl)ethyl)piperazin-1-yl)methanone); 1  µM; synthesized by Sudia 
MediTech; Ding et al., 2009); doxorubicin (1  µM; Sigma-Aldrich); 
cytochalasin D (4  µM; Sigma-Aldrich); monastrol (100  µM; Toc-
ris Bioscience); nocodazole (2.5 µg/ml; Sigma-Aldrich); and NMS-
P715 (2 µM; EMD Millipore).
Antibodies
Antibodies against Cep192 (1–211 aa; used at 0.5 µg/ml), SAS-6 
(501–657 aa; used at 0.5 µg/ml), and Plk4 (501–657 aa; used at 1 µg/
ml) were previously described (Wong et al., 2015). The following an-
tibodies were purchased from commercial sources, with their work-
ing concentrations indicated in parentheses: anti-Trim37 (1:2,000 for 
Western blotting; A301-174A; Bethyl Laboratories, Inc.), anti-Usp28 
(1:1,000 for Western blot; ab126604; Abcam), anti-Usp28 (1:100 
for immunofluorescence; HPA006778; Sigma-Aldrich), anti-53BP1 
(1:5,000), anti-Cep152 (1:2,000; Abcam), anti-Cdk5rap2 (1:4,000; 
Abcam), GTU-88 (anti–γ-tubulin; 1:1,000; Sigma-Aldrich), anti-peri-
centrin (1 µg/ml; Abcam), anti-CPAP (1:400; Proteintech), anti-p53 
(1:100 for Western blot; OP43; EMD Millipore), anti-p53 (1:500 for 
immunofluorescence; OP140; EMD Millipore), anti-p21 (1:1,000; 
#2947; Cell Signaling Technology), DM1A (anti–α-tubulin; 1:5,000; 
Sigma-Aldrich), anti-GAP DH (1:1,000; 14C10; Cell Signaling Tech-
nology), PCM-1 (1:400; #5259; Cell Signaling Technology), and Fab 
fragment (goat anti–rabbit IgG; 30 µg/ml; Jackson ImmunoResearch 
Laboratories, Inc.). Secondary antibodies were purchased from Jack-
son ImmunoResearch Laboratories, Inc.
Cell lines
RPE-1 cells were obtained from ATCC. RPE-1 cells and all deriv-
ative cell lines generated in this study (Table S1) were grown in 
DMEM/F12 media containing 10% FBS, 100 µg/ml streptomycin, 
and 100 U/ml penicillin.
Cells were maintained at 37°C and 5% CO2. For generation 
of CRI SPR/Cas9-mediated knockout cell lines, specific gRNAs 
(TP53BP1Δ, 5′-CTG CTC AAT GAC CTG ACT GA-3′; USP28Δ, 5′-TGA 
GCG TTT AGT TTC TGC AG-3′; TRIM37Δ, 5′-CTC CCC AAA GTG 
CAC ACT GA-3′) were cloned in lentiCRI SPR v2 (#52961; Addgene; 
Sanjana et al., 2014) or PX459 (#48139; Addgene; Ran et al., 2013). 
RPE-1 cells were transiently transfected with gRNA and Cas9 con-
taining plasmids using Lipofectamine 3000 (Thermo Fisher Scientific) 
according to the manufacturers’ guidelines. Transfected cells were 
grown in 150 nM centrinone for 2 wk, with media exchange every 5 d.  
Cells were grown for an additional 3–5 d in centrinone-free medium 
before colonies were isolated. Clones were tested by Western blotting. 
For generation of H2B-mRFP–expressing cell lines, H2B-mRFP was 
cloned into the lentiviral vector pCDH-EF1 with XbaI–NotI restriction 
sites. This plasmid and lentivirus packaging vectors (pCAG-HIVgp 
and pCMV-VSV-G-RSV-Rev from H. Miyoshi, RIK EN BioResource 
Center, Ibaraki, Japan) were cotransfected into HEK-293T cells using 
Fugene HD (Promega). 48 h after transfection, virus-containing cul-
ture supernatant was harvested and added to the growth medium of 
RPE-1 cells along with 8 µg/ml polybrene (EMD Millipore). Popula-
tions of each cell line expressing H2B-mRFP were selected by FACS. 
To knock down TP53 (p53), RPE-1 cells were infected with a lentivirus 
containing sh-p53 made using the plasmid shp53 pLKO.1 puro (19119; 
Addgene; Godar et al., 2008). Positive selection of sh-p53–expressing 
cells was performed 2 d after infection with 10 µg/ml puromycin.
CRI SPR/Cas9 screen
The CRI SPR/Cas9 screen was performed using the human GeCKO 
v2 library (#1000000048; Addgene; Sanjana et al., 2014). 3.2 million 
RPE-1 cells were infected with 12.8 million infectious virus parti-
cles in a 15-cm plate using 20 ml DMEM/F12 medium and 8 µg/ml 
polybrene. Cells were treated with 150 nM centrinone. After 2 d, cells 
were transferred to 32 15-cm plates (first screen) or 75 15-cm plates 
(second screen). Centrinone treatment was continued for 3 wk. After 3 
wk, growing colonies were isolated. Isolated clones were further ana-
lyzed in a secondary Mdm2i screen (first and second screen) as well as 
pooled and analyzed by Illumina sequencing (first screen).
Mdm2 inhibitor screen
Wild-type RPE-1 cells and clones isolated from the centrinone 
CRI SPR/Cas9 screen were plated as duplicates into 12-well plates and 
treated with either 1 µM Mdm2 inhibitor or DMSO vehicle control for 
1 wk. Clones that arrested in 1 µM Mdm2 inhibitor but not in DMSO 
were harvested. The different gRNA sequences of each cell clone 
were amplified with oligos: (1) 5′-TCC GCT CGA GTG TGG GCG ATG 
TGC GCT CTG-3′ and (2) 5′-GCG GGA TCC GCA ATG GAC TAT CAT 
ATG CTT ACC GTA ACT TGA AAG TAT TTCG-3′. The PCR product, 
which contains a pool of different gRNAs, was cloned into a vector 
with BamHI–XhoI restriction sites. From each cell clone, the gRNA 
sequence of 10 plasmid clones was determined by Sanger sequencing.
Immunofluorescence and quantification of nuclear and  
centrosomal signals
RPE-1 control and the 53BP1Δ, USP28Δ, and TRIM37Δ knockout cell 
lines were treated for 5 d with 150 nM centrinone or DMSO. 1 day 
before fixation, 8,000 cells per well were plated into 96-well plates. 
Cells were fixed in ice-cold methanol for 7 min at −20°C, washed twice 
with washing buffer (PBS containing 0.1% Triton X-100), and blocked 
with blocking buffer (PBS containing 2% BSA, 0.1% Triton X-100, 
and 0.1% NaN3) for 1 h. Cells were washed three times with washing 
buffer and incubated for 1 h with the first antibody (concentrations as 
indicated earlier). Cells were washed three times with washing buffer, 
incubated for 1 h with the secondary antibody, and stained for DNA 
with Hoechst 33342 dye. For double labeling with primary antibodies 
from the same host species (Fig. S3 A), fixed cells were first incubated 
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with the first primary antibody (rabbit anti-Cep192), which was then 
blocked with an AffiniPure Fab fragment (goat anti–rabbit IgG) before 
incubation with the second primary antibody (rabbit anti-PCM1). Effi-
cient blocking of the first primary antibody by the Fab fragments was 
confirmed, because an anti-rabbit secondary antibody did not recognize 
the blocked first primary antibody. Cells were washed three times with 
washing buffer before inspection. Images were acquired on a CV7000 
spinning disk confocal system (Yokogawa Electric Corporation) 
equipped with a 40× (0.95 NA) or 60× (water, 1.2 NA) U-PlanApo 
objective and 2,560 × 2,160-pixel sCMOS camera (Andor Technol-
ogy) at 2 × 2 binning. Image acquisition was performed using CV7000 
software. Nuclear signal intensity measurements were performed auto-
matically using CV7000 analysis software. The nuclear area was deter-
mined using Hoechst 33342 staining as reference. To measure nuclear 
p53 signals, the mean gray value of the cytoplasmic signal, measured 
in a 2-µm area surrounding the nucleus, was subtracted from the mean 
gray value of the nuclear signal.
Analysis of mitosis and daughter cell fate
To study the correlation between mother cell prometaphase duration 
and daughter cell fate, RPE-1 control and TP53BP1Δ, USP28Δ, and 
TRIM37Δ knockout cell lines expressing H2B-mRFP were seeded into 
96-well polystyrene plates at 2,000 cells/well, 12–14 h before imaging. 
Cells were treated with 100 µM monastrol and immediately imaged on 
the CV1000 or CQ1 spinning disk confocal systems (Yokogawa Elec-
tric Corporation) with a 20× 0.75 NA U-PlanApo objective at 37°C and 
5% CO2. Image acquisition and data analysis were performed using 
CellVoyager software and ImageJ, respectively. 20–30 fields/well were 
imaged. 5 × 2-µm z-sections in RFP (25% power, 100 ms, 30% gain) 
were acquired in each field at 10-min intervals for 6 h. The plate was 
then removed from the microscope, and wells were washed twice with 
warm medium. The plate was returned to the microscope, and imaging 
resumed for 2 h at 10-min intervals and then for an additional 48 h at 
20-min intervals. The mitotic fate of daughter cells was analyzed as 
well as clear chromosome missegregation events (formation of daugh-
ter cells with micronuclei).
To study mitosis of RPE-1 control and 53BP1Δ, USP28Δ, and 
TRIM37Δ knockout cells, cells expressing H2B-mRFP were treated for 5 
d with DMSO or 150 nM centrinone before imaging. Cells were seeded 
into 96-well polystyrene plates at 10,000 cells/well, 24 h before imaging. 
Images were acquired on a CV7000 spinning disk confocal system (Yo-
kogawa Electric Corporation) with a 40× 0.95 NA U-PlanApo objective 
and 2,560 × 2,160-pixel sCMOS camera (Andor Technology) at 2 × 
2 binning. Image acquisition was performed using CV7000 software. 
20–30 fields/well were imaged. 5 × 2-µm z-sections in RFP (30% power, 
150 ms) channels were captured in each field at 4-min intervals for 8 h.
Tetraploid cell arrest assay
RPE-1 control and knockout cell lines expressing H2B-RFP were seeded 
into a 96-well polystyrene plate at 1,000 cells/well, 24 h before treat-
ment. Cells were treated with 4 µM cytochalasin D (Sigma-Aldrich) for 
24 h and washed five times with warm medium. After drug washout, the 
plate was imaged on the CQ1 system with a 20× 0.75 NA U-PlanApo 
objective. Image acquisition and data analysis were performed using 
CellVoyager software and ImageJ, respectively. 25–30 fields/well were 
imaged. For each field, five z-sections at 2-µm intervals were acquired 
in the RFP channel (25% power, 150 ms, and 30% gain) at 20-min in-
tervals for 72 h. Tetraploid cells were identified as cells with two nuclei.
Proliferation assays
For each condition in the passaging assays, cells were seeded in trip-
licate into 10-cm plates at 100,000 cells/plate. Centrinone and Mdm2 
inhibitor were added at the indicated concentrations. At 96-h intervals, 
plates were harvested, counted, and replated at 100,000 cells/plate. 
Cell counting was performed using a TC10 or TC20 automated cell 
counter (Bio-Rad Laboratories). For determination of doubling times, 
DMSO-treated control RPE1 and TRIM37Δ mutant cells, as well as 
TRIM37Δ mutant cells treated with centrinone for >2 wk, were plated 
into six-well dishes at 25,000 cells per well. For 3–4 d, at 24-h inter-
vals, wells were harvested and counted using a TC20 automated cell 
counter (Bio-Rad Laboratories).
Microtubule regrowth assay
RPE1 control and TRIM37Δ mutant cells were treated for 5 d with 
DMSO or 150 nM centrinone. Cells were seeded into 96-well plates 
and treated for 2 h with 2.5 µg/ml nocodazole to depolymerize microtu-
bules. Cells were washed five times with PBS and incubated for 4 min in 
fresh prewarmed growth medium at 37°C to allow microtubule polym-
erization. Cells were fixed with ice-cold methanol for 7 min at −20°C 
and stained for Cep192, α-tubulin, and DNA. Fixed cells were kept in 
PBS until imaging. Images were acquired on a CV7000 spinning disk 
confocal system (Yokogawa Electric Corporation) with a 60× (water, 
1.2 NA) U-PlanApo objective and 2,560 × 2,160-pixel sCMOS camera 
(Andor Technology) at 1 × 1 binning. Image acquisition and processing 
was performed using CV7000 software and ImageJ, respectively.
Western blotting
Asynchronously growing cells from 10-cm plates were harvested at 
50–80% confluence and lysed by sonication in RIPA buffer plus prote-
ase and phosphatase inhibitor cocktail (Thermo Fisher Scientific). Cell 
extracts were stored at −80°C. Before use, extract concentrations were 
normalized based on a Bio-Rad Protein Assay (Bio-Rad Laboratories). 
For every sample, 30 µg protein/lane was run on Mini-PRO TEAN gels 
(Bio-Rad Laboratories) and transferred to PVDF membranes using a 
TransBlot Turbo system (Bio-Rad Laboratories). Blocking and anti-
body incubations were performed in TBS-T plus 5% nonfat dry milk or 
in TBS-T plus 5% BSA. Detection was performed using HRP-conju-
gated secondary antibodies (GE Healthcare) with WesternBright Sirius 
(Advansta) or SuperSignal West Femto (Thermo Fisher Scientific) sub-
strates. Membranes were imaged on a ChemiDoc MP system (Bio-Rad 
Laboratories). Membranes were stripped and reprobed with antibodies 
against α-tubulin or GAP DH as loading controls.
Analysis of p53 expression by Western blotting
The expression of p53 upon exposure to different type of stresses 
(centrosome depletion, DNA damage, and Mdm2 inhibition) was an-
alyzed by Western blotting. Control RPE1 and 53BP1Δ, USP28Δ, and 
TRIM37Δ knockout cells were incubated in 10-cm plates for 24 h with 
1 µM doxorubicin (DNA damage), for 24 h with 1 µM Mdm2 inhibitor, 
or for 48 h with 150 nM centrinone before harvesting. Western blotting 
was performed with the indicated antibodies as described earlier.
Online supplemental material
Fig. S1, which is related to Fig. 1, shows the results from the CRI SPR/
Cas9 screen. Fig. S1 A lists all gRNAs identified in the isolated clones. 
Fig. S1 B lists all gRNAs that were identified by deep sequencing of 
the pooled clones from screen 1. Fig. S2 is related to Fig. 2. Fig. S2 A 
shows the locations of the gRNAs used to generate the single deletion 
mutants in the TP53BP1, USP28, and TRIM37 genes, along with the 
locations in the corresponding proteins. Fig. S2 B shows the absence 
of 53BP1 and USP28 from nuclei in the TP53BP1Δ and USP28Δ 
knockouts, respectively. Fig. S2 C shows the efficiency of centrosome 
depletion in the TP53BP1Δ, USP28Δ, and TRIM37Δ mutants compared 
with RPE1 control. Fig. S2 D shows the quantification in two additional 
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experiments of nuclear p53 in TP53BP1Δ, USP28Δ, and TRIM37Δ 
knockout cells compared with RPE1 control after 5 d of centrinone 
treatment. Fig. S2 E shows p53 levels after 12, 24, and 48 h of centrinone 
treatment. Fig. S2 F shows results of experiments performed to rescue 
mitotic timing in centrinone-treated cells with the Mps1 inhibitor 
NMS-P715, including a Western blot of p53 levels of centrinone- and 
NMS-P715–treated cells, mitotic duration in centrinone- and NMS-
P715–treated cells, and a plot of the percentage of cells that fail 
chromosome segregation and cytokinesis upon centrinone and NMS-
P715 treatment. Fig. S3 is related to Figs. 4 and 5. Fig. S3 A shows 
colabeling of PCM-1 and Cep192 in DMSO- and centrinone-treated 
TRIM37Δ cells. Fig. S3 B shows quantification of ectopic foci staining 
for centrosomal markers in interphase cells. Fig. S3 C shows staining of 
centrosomal markers in mitotic DMSO-treated TRIM37Δ cells, along 
with centrinone-treated TP53BP1Δ and USP28Δ cells. Fig. S3 D shows 
the number of mitotic cells that were examined for the analysis shown 
in Figs. 4 D and S3 C as well as the quantification of centrosomal-
component foci in DMSO- and centrinone-treated mitotic TRIM37Δ 
cells. Fig. S3 E plots mitotic duration for bipolar and multipolar mitosis 
in DMSO- and centrinone-treated TRIM37Δ cells. Fig. S3 F shows a 
table of p-values for the experiment shown in Fig. 5 C. Fig. S3 G shows 
doubling times for long-term DMSO- or centrinone-treated TRIM37Δ 
cells. Online supplemental material is available at http ://www .jcb .org /
cgi /content /full /jcb .201604081 /DC1.
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